SVRA vs INSM vs RARE vs PRAX vs ACAD

For growth investors, Insmed Incorporated (INSM) is the stronger pick with 66.

7% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate Savara Inc. (SVRA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Insmed Incorporated (INSM) delivered a total return of +221.

7%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: INSM returned +793. 5% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Insmed Incorporated (INSM) is the lower-risk stock at 0.

54β versus Praxis Precision Medicines, Inc. 's 1. 55β — meaning PRAX is approximately 186% more volatile than INSM relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 104% for Insmed Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Insmed Incorporated (INSM) is pulling ahead at 66.

7% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -45. 5% for Savara Inc.. Over a 3-year CAGR, INSM leads at 35. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -210. 5% for Insmed Incorporated — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -194. 0% for INSM. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for INSM: 107.

2% to $217. 11.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Insmed Incorporated (INSM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

54), +793. 5% 10Y return). Praxis Precision Medicines, Inc. (PRAX) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INSM: +793. 5%, PRAX: -20. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SVRA is a small-cap quality compounder stock; INSM is a mid-cap high-growth stock; RARE is a small-cap high-growth stock; PRAX is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.